The Better Business Bureau is asking consumers to keep up their guard following a run of scams promoting popular weight loss ...
Friendly” labels on the packaging are becoming more common as a growing number of Americans try obesity drugs like Wegovy and ...
The FDA is requesting that manufacturers of three GLP-1 receptor agonists remove information on risk for suicidal ideation ...
The popularity of weight-loss drugs like Ozempic and Wegovy has surged in recent years. A local weight loss specialist speaks ...
Discontinuing obesity medicines often means the weight comes back and people lose the cardiovascular and metabolic benefits ...
1hon MSN
Healthy returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference
Novo Nordisk's CEO spoke about GLP-1 pricing and Pfizer's CEO spoke about the company's obesity ambitions while at the ...
The removal request is based on a ‘comprehensive review of available data’ that showed no increased risk of suicidal ideation and behavior.
MedPage Today on MSN
FDA Says to Drop Suicide Warning From GLP-1 Drug Labels
Concerns about GLP-1 drugs indicated for weight loss were first raised after the FDA's Adverse Event Reporting System ...
After a period of diversification, Novo Nordisk is returning to its roots by focusing on the 2 billion people with diabetes, ...
The Food and Drug Administration on Tuesday told Eli Lilly and Novo Nordisk to remove warnings about the risk of suicidal ...
Oral weight-loss drugs could account for a third or more of the overall GLP-1 market by 2030, a Novo Nordisk executive said ...
A more detailed review of data by the FDA showed that GLP-1 drugs do not increase the risk of suicidal ideation or behavior.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback